Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy –1.3% vs. –0.9% [–14 vs. –9 mmol/mol], estimated treatment difference [ETD] –0.4% [95% CI –0.6, –0.3] [–5 mmol/mol (–6, –3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (–1.4% vs. –0.9% [–15 vs. –9 mmol/mol], ETD –0.5% [95% CI –0.7, –0.4] [–6 mmol/mol (–7, –5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product −4.7 vs. −3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in the randomised, open-label, multinational 52-week PIONEER 2 trial, oral semaglutide 14 mg resulted in a significantly greater reduction in CRP compared with empagliflozin 25 mg.23”
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [20]
In the citing paper
“In PIONEER 2, oral semaglutide reduced CRP by 30%, whereas empagliflozin had no effect despite similar approximately 4% weight loss (24).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [24]
In the citing paper
“In the PIONEER program, four thyroid malignancies occurred in semaglutide-treated patients, versus one in the comparator group”
From Safety of Semaglutide (2021) · cites this paper as [15]
In the citing paper
“The ‘PIONEER’ series of trials [21–30] demonstrated that oral semaglutide has a positive impact on average HbA1c levels and weight reduction compared with several other drug classes (SGLT-2 inhibitor, DPP-4 inhibitor, another GLP-1RA, insulin and placebo).”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [22]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Self-citationSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†An episode that is severe, according to theADAclassification (requires assistanceof anotherperson to actively administer carbohydrate, glucagon, or other corrective action) (29).”
BackgroundUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Self-citationSorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Cited by
Items 201–300 of 482
Morieri, M. L., Candido, R., Frontoni, S., Disoteo, O., Solini, A., Fadini, G. P., for the PIONEERING EXPERIENCE study group, Bellanti, F., Caprio, M., Cutolo, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01490-6 · Cited by 14
Effect of empagliflozin on weight in patients with prediabetes and diabetes
Sanjari, M., Hadavizadeh, M., Sadeghi, N., & Naghibzadeh‐Tahami, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-83820-7 · Cited by 14
Chan, M. K., Dimitriou, A., & Lam, S. (2020) · Cardiology in Review · doi:10.1097/crd.0000000000000351 · Cited by 14
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Laursen, H. V. B., Jørgensen, E. P., Vestergaard, P., & Ehlers, L. H. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01268-5 · Cited by 14
Novel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Jarrar, M., Al‐Bsheish, M., Alshahri, B. K., Bamashmoos, M., Alnaimi, M. I., Alsayil, S., Basager, S., Rawashdeh, M. A., & Al-Rawashdeh, A. B. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s534066 · Cited by 14
Ocular Effects of GLP-1 Receptor Agonists: A Review of Current Evidence and Safety Concerns
Albanese, G. M., Visioli, G., Alisi, L., Giovannetti, F., Lucchino, L., Armentano, M., Catania, F., Marenco, M., & Gharbiya, M. (2025) · Diabetology · doi:10.3390/diabetology6100117 · Cited by 15
Campos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Ehlers, L. H., Lamotte, M., Ramos, M., Sandgaard, S., Holmgaard, P., Kristensen, M. M., & Ejskjær, N. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01221-3 · Cited by 13
Current Weight Loss Medications: What Plastic Surgeons Should Know
Wirth, P. J., Shaffrey, E. C., Bay, C. C., & Rao, V. K. (2023) · Aesthetic Surgery Journal · doi:10.1093/asj/sjad304 · Cited by 13
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
Tsilingiris, D., & Kokkinos, A. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155741 · Cited by 16
Lavernia, F., & Blonde, L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798638 · Cited by 13
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Liu, Y., & Luo, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0873-2 · Cited by 15
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
Suzuki, R., Amadid, H., Major‐Pedersen, A., & Yabe, D. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14219 · Cited by 12
Xie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Zu, N., & Shi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15624 · Cited by 14
Candido, R., Loreto, C. D., Desenzani, P., Pantanetti, P., Romano, C., Settembrini, S., Solerte, S. B., & Fadini, G. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01625-3 · Cited by 14
Lautsch, D., Alsumali, A., McLeod, E. J., Kuang, Y., He, J. N., Singh, R., Nevo, A., Arnet, U. A., Uyei, J., & Rajpathak, S. N. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00975-y · Cited by 12
Araki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14536 · Cited by 14
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
Pantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
Hsu, C., Zeng, B., Liang, C., Zeng, B., Hung, C., Stubbs, B., Chen, Y., Lei, W., Chen, J.-J., Chen, P., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178202 · Cited by 12
Wu, R., Xing, B., Huang, Y., Zhou, Z., Sun, B., Yu, L., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554795 · Cited by 11
Jebeile, H., Danielsen, Y. S., Sumithran, P., Lorien, S. J., Jardine, I. R., Baur, L. A., & Lister, N. B. (2025) · Obesity Reviews · doi:10.1111/obr.70049 · Cited by 14
Singh, A. K., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102436 · Cited by 13
Shabutdinova, O. R., Dautov, A. R., Samkov, A. A., Kononenko, A. V., Sargaliev, A. F., Davletshin, A. R., Andresova, P. A., Zarbeeva, K. R., Torshkhoeva, D. A., Rakhmonkulov, U. A., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13197 · Cited by 17
Dang, L. E., Fong, E., Tarp, J. M., Clemmensen, K. K. B., Ravn, H., Kvist, K., Buse, J. B., van der Laan, M. J., & Petersen, M. L. (2023) · Journal of Clinical and Translational Science · doi:10.1017/cts.2023.656 · Cited by 14
BALDASSARRE, M. P. A., Dalmazi, G. D., Coluzzi, S., Carrieri, F., Febo, F., Centorame, G., Cassino, P., Piacentino, L., Baroni, M. G., Consoli, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113054 · Cited by 13
Franch‐Nadal, J., Malkin, S. J. P., Hunt, B., Martín, V., Estébanez, M. G., & Vidal, J. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02156-8 · Cited by 11
Gao, L., Cheng, Z., Su, B., Su, X., Song, W., Guo, Y., Liao, L., Chen, X., Li, J., Tan, X., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14926 · Cited by 11
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 12
Evans, M., Morgan, A. R., Bain, S. C., Davies, S., Hicks, D., Brown, P., Yousef, Z., Dashora, U., Viljoen, A., Beba, H., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-021-01201-z · Cited by 10
Comparing medication persistence with oral and subcutaneous semaglutide in a real-world setting
Conti, M., Pontiggia, L., Vergani, M., Muraca, E., Cannistraci, R., Perra, S., Lattuada, G., Perseghin, G., & Ciardullo, S. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02424-9 · Cited by 12
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
Bujdei-Tebeică, I., Mihai, D. A., Stoian, A. P., Ștefan, S., Stoicescu, C. I., & Serafinceanu, C. (2025) · Medicina · doi:10.3390/medicina61081399 · Cited by 11
Recent advances and trends in oral absorption enhancements of GLP-1 receptor agonist formulations
Kim, D.-H., & Kim, J.-E. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00762-6 · Cited by 10
Yu, M., Wang, T., Xu, C., Bi, Y., Gao, L., Wang, G., Xiang, G., Xue, Y., Yang, T., Kang, D., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70197 · Cited by 10
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
Semaglutide attenuates neuroinflammation in male mice
Rausch, D. M., Ludwig, M. Q., Bentsen, M. A., Hansen, S. N., Secher, A., Holst, D., Moreno, J., Das, V., Egerod, K. L., Bjerregaard, A.-M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74038-4 · Cited by 10
Wu, T., Wong, C. K. H., Lui, D. T. W., Wong, S. K., Lam, C. L. K., Chung, M. S. H., McAllister, D., Welbourn, R., & Dixon, J. B. (2023) · BJS Open · doi:10.1093/bjsopen/zrad077 · Cited by 12
Wełnicki, M. T., Gorczyca-Głowacka, I., Mamcarz, A., Filipiak, K. J., Wożakowska−Kapłon, B., Barylski, M., Szymański, F. M., Kasprzak, J. D., Grabowski, M., & Dzida, G. J. (2022) · Kardiologia Polska · doi:10.33963/kp.a2022.0282 · Cited by 15
Hu, S., Su, X., Deng, X., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.701446 · Cited by 10
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Berković, M. C., Režić, T., Bilić-Čurčić, I., & Mrzljak, A. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i20.6759 · Cited by 10
Meier, J. J., Bardtrum, L., CHENG, A. Y. Y., Malling, B., Montanya, E., Wagner, L., & Pratley, R. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14957 · Cited by 9
Self-citationSemaglutide Is a New Once-Daily Oral Medication to Treat Type 2 Diabetes
Blakely, K. K., & Weaver, K. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.07.005 · Cited by 9
Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review
Sofogianni, A., & Τζιόμαλος, Κ. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01478-9 · Cited by 10
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics
Osaka, H., Nishida, K., & Kanazawa, T. (2024) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.185 · Cited by 12
Petrova, L., Andreevska, K., Parvova, I., & Petkova, V. B. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e132148 · Cited by 9
Won, H., Cho, J., & Lee, S. (2025) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2025.33.e3 · Cited by 8
Dungan, K. M., Bardtrum, L., Christiansen, E., Eliasson, J., Mellbin, L., Woo, V. C., & Vilsbøll, T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01413-5 · Cited by 10
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis
Zhang, L., Hua, Z., Fang, Z., Wei, J., & Yang, L. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2483 · Cited by 12
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
Powell, J., Piszczatoski, C., & Taylor, J. R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.07.017 · Cited by 8
Overgaard, R. V., Birkhan, O. A., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70769 · Cited by 9
Boye, K. S., Poon, J. L., Landó, L. F., Sapin, H., Huh, R., Wang, M., WILLIAMSON, S. E., & Patel, H. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01620-8 · Cited by 8
Bergman, B. K., Rosenstock, J., Garvey, W. T., Batterham, R. L., Chen, Y., Liu, M., Sharma, P., Karanikas, C. A., & Thieu, V. T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16337 · Cited by 9
Self-citationPIONEER REAL Italy: Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes
Manti, R., Cosmo, S. D., Desenzani, P., Ferrara, L., Girelli, A., Memoli, G., Bisio, A., Braae, U. C., Deinega, A., Berra, C., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01719-6 · Cited by 9
Self-citationElangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Nekidy, W. S. E., Hasan, H., Abidi, E., Sayegh, L. A., Dajani, R. Z., El-Kaissi, S., Hegazin, S. B., & Mallat, J. (2025) · Hospital Pharmacy · doi:10.1177/00185787251340645 · Cited by 8
Joshi, S., Rajput, R., Chowdhury, S., Singh, A. K., Bantwal, G., Das, A. K., Unnikrishnan, A., Saboo, B., Kesavadev, J., Ghosal, S., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102508 · Cited by 8
Nikitin, D., Lin, G. A., Campbell, J. D., Hansen, R. N., Brouwer, E., Chen, Y., Herron-Smith, S., Agboola, F. O., & Pearson, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.6.680 · Cited by 9
Lopes, A. C., Roque, F., Lourenço, O. M., Herdeiro, M. T., & Morgado, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2172159 · Cited by 7
Swift, C., Frazer, M., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15516 · Cited by 7
Chen, J.-J., Hsu, C., Hung, C., Suen, M.-W., Wang, H.-Y., Yang, W.-C., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020608 · Cited by 7
Pharmacological Management of Diabesity: Current and Emerging Therapies
Galasso, M., Caporusso, M., Volatile, A., Verde, L., Esposito, K., Giorgino, F., Perrini, S., Colao, A., Barrea, L., & Muscogiuri, G. (2026) · Current Obesity Reports · doi:10.1007/s13679-025-00681-5 · Cited by 6
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 7
Welch, M., Forst, T. M., Jia, W., del Pino, P. O., Denning, M., Wu, W.-S., Li, J., Liu, R., EIFU, M., Chen, Y., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00800-7 · Cited by 7
Self-citationCosta, S., Miranda, C., Elefante, A., Vallone, V., Vinci, C., Borroni, F., Brandoni, G., Labate, A. M. M., Pomo, F. L., & Strazzabosco, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16314 · Cited by 7
Liang, L., Yu, L., He, Y., Liu, L., Yuan, H., Hu, Y., & Sun, J. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.08.009 · Cited by 7
Lee, E. Y., Cho, J., Lee, W. J., Kim, N. H., Kim, J. H., & Lee, B. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110884 · Cited by 6
Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Bissonnette, R., Eichenfield, L. F., Simpson, E. L., Thaçi, D., Kabashima, K., Thyssen, J. P., Guttman‐Yassky, E., Nunes, F. P., Gamalo, M., Ahmad, F., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18881 · Cited by 7
Pulleyblank, R., & Larsen, N. B. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00416-z · Cited by 7
Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists
Rodriguez‐Araujo, G. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000197 · Cited by 8
Fazioli, K., Rind, D. M., Guzauskas, G. F., Hansen, R. N., & Pearson, S. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.9.1072 · Cited by 7
Oral semaglutide: the innovation in type 2 diabetes management
Shestakova, M. V., Шамхалова, М. Ш., Galstyan, G. R., Ruyatkina, L. A., & Суплотова, Л. А. (2021) · Diabetes Mellitus · doi:10.14341/dm12790 · Cited by 6
Self-citationKroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
Sabbagh, M. N., Boschini, C., Cohen, S., Fugger, M., Jessen, F., Dandanell, S., Pedersen, S. D., Tarazona, L. R. S., & Aroda, V. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70076 · Cited by 9
Abusedera, O., Sherif, J., Smida, M., & Fredericks, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248734 · Cited by 5
Nomoto, H., Furusawa, S., Yokoyama, H., Suzuki, Y., Izumihara, R., Oe, Y., Takahashi, K., Miya, A., Kameda, H., Cho, K. Y., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae213 · Cited by 5
Energy Landscapes and Structural Ensembles of Glucagon-like Peptide-1 Monomers
Keith, A. D., Brichtová, E. P., Barber, J. G., Wales, D. J., Jackson, S., & Röder, K. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c01794 · Cited by 5
Song, R., Hou, Q., Zhang, X., Zhao, W., Liu, G., Li, M., Zhang, X., & Ji, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376850 · Cited by 5
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
Delgado, E., Morales, C., Abreu, C., Verdugo, A. A., Carbonell, A. M. P., González, A. C., Valero, J. A. G., López, V. G., Rasmussen, C. L., Scheuer, S. H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16523 · Cited by 6
GLP-1R signaling does not modify the severity of experimental graft versus host disease
Yusta, B., Wong, C. K., Matthews, D., Koehler, J. A., Baggio, L. L., Bang, K. W. A., & Drucker, D. J. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102235 · Cited by 7
Efficacy and Safety of Oral Semaglutide in Managing Type 2 Diabetes in India: A Real-World Study
Ray, S., Ray, A., Goutam, S., & Mitra, A. (2024) · Clinical Diabetology · doi:10.5603/cd.102374 · Cited by 5
Hammerman, A., Moore, C. M., Aboalhasan, E., Azuri, J., & Arbel, R. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.01.027 · Cited by 6
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice
Karásek, D. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.018 · Cited by 8
Pharmacologic treatment of obesity
Jung, H. N., & Jung, C. H. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.7.408 · Cited by 5
Evans, M., Berry, S., Nazeri, A., Malkin, S. J. P., Ashley, D., Hunt, B., & Bain, S. C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14917 · Cited by 5
Xu, B., Kang, B., Li, S., Chen, J., & Zhou, J. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-01924-0 · Cited by 7
Ortiz-Seller, A., Ortiz-Seller, D., Morcillo, E. J., & Ortiz, J. L. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02071-2 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Forzano, I., Narciso, V., Canonico, M. E., Castiello, D. S., Florimonte, D., Manzi, L., Semplice, F., Vallone, D. M., Cristiano, S., Spinelli, A. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15031108 · Cited by 5
Metadata
- Authors
- Rodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., PIONEER 2 Investigators, Cruz, P., Loredo, L. D., Luquez, C., Moisello, M., Augusto, G. A., Castro, M., Canani, L., Akrap, B., Bulum, T., Rahelic, D., Sunic-Grcic, I., Tusek, S., Avramidis, I., Benroubi, M., Didangelos, T., Karousos, G., Pagkalos, E., Sampanis, C., Somali, M., Domboróczki, Z., Faludi, P., Gaál, Z., Kis-Gombos, P., Kocsis, G., Marton, Z., Sudár, Z., Buscemi, S., Di Carlo, A., Dotta, F., Gambineri, A., Lauro, D., Maranghi, M., Arciszewska, M., Gumprecht, J., Matuszewska, K., Skokowska, E., Stasinska, T., Feofanova, S., Filippova, E., Galstyan, G., Gaysina, L., Kunitsyna, M., Suplotova, L., Antic, S., Djukic, A., Mitrovic, M., Pesic, M., Stokic, E., Jodar, E., Martínez, E., Raya, P. M., Montanya, E., Portillo, C. M., Vera, M. P., Fernández, M. R., San Jose, P., Riera, M. T., Boonyavarakul, A., Deerochanawong, C., Sriwijitkamol, A., Ajani, D., Armas, E., Barbel-Johnson, K., Bartilucci, D., Bonabi, G., Busch, R., Butuk, D., Cannon, K., Chase, C., Chaykin, L., Cheekati, V., Davis, T., Delgado, B., Farris, N., Graves, M., Ha, C., Harper, L., Herring, S., Hewitt, M., Hsia, D., Jackson, R., Jardula, M., Joyce, M., Juarez, M., Kapoor, A., Karounos, D., Kayne, D., Lacour, A., Ledesma, G., Lingvay, I., Lipetz, R., Lomboy, J., Lynd, S., Morawski, E., Morin, R., Murphy, R., Overcash, J. S., Pullman, J., Rodbard, H. W., Rosenstock, J., Ruoff, G., Steenkamp, D., Toro, H., Trachtenbarg, D., Tulloch, B., Weisbrot, A., & Wright, A.
- Affiliations
- Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Novo Nordisk (Denmark) (DK)
- ORCID
- Lindberg, Søren Østergaard
- Augusto, Gustavo Akerman
- Bulum, Tomislav
- Avramidis, Iakovos
- Didangelos, Triantafyllos
- Buscemi, Silvio
- Dotta, Francesco
- Gambineri, Alessandra
- Lauro, Davide
- Maranghi, Marianna
- Galstyan, Gagik
- Boonyavarakul, Apussanee
- Sriwijitkamol, Apiradee
- Busch, Robert
- Herring, Sharon
- Hsia, Daniel
- Overcash, J. Scott
- Steenkamp, Devin
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-10-07
- Volume
- 42
- Issue
- 12
- Pages
- 2272-2281
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2974621372
- Cited by
- 463
- References
- 37
- Citations by year
- 2026: 53 · 2025: 85 · 2024: 78 · 2023: 55 · 2022: 64 · 2021: 59 · 2020: 60 · 2019: 8
- FWCI
- 38.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Use Siena air (University of Siena) (submittedVersion)
- Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, cc-by-nc-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- oral semaglutide, empagliflozin, type 2 diabetes, metformin failure, GLP-1 receptor agonists, SGLT2 inhibitors, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, drug safety, treatment policy estimand
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.